



ASX ANNOUNCEMENT

22 January 2019

**Company Announcements Office
ASX Limited
Exchange Centre
20 Bridge Street
SYDNEY NSW 2000**

CardieX Receives Convertible Note Subscription from C2 Ventures Pty Ltd

Further to the Company's announcement of 14 January 2019 CardieX Limited ("CardieX" or the "Company") is pleased to announce completion of the application for \$2.5m in Convertible Notes by C2 Ventures Pty Ltd ("C2V") under a Convertible Note facility entered into by deed between CardieX and C2V.

The subscription of \$2.5m by C2V comes as CardieX readies itself for completion of the inHealth Medical Services acquisition and provides completion certainty to the Company as it readies for the second investment tranche later in January 2019.

The interim subscription by C2V is in advance of shareholder approval under a Convertible Note facility that would be later discharged on approval of the issue of shares up to their 19.99% total holding limit under *the Corporations Act 2001*.

On this basis C2V would have a further \$1,925,000 in shares issued to it (64,166,667 additional shares at the December 2018 placement price) which would bring the total holding of C2V to 139,166,667 (~19.96% of the Company post issue) immediately after the meeting. The balance of the outstanding facility amount would then be converted at later dates to ensure compliance with the takeover provisions of *the Corporations Act 2001*.

As previously disclosed Directors Mr Niall Cairns and Mr Craig Cooper own and control C2V meaning that shareholder approval for the conversion of the Convertible Notes into shares is required in conjunction with ASX LR10.11.

To this extent CardieX is also pleased to confirm that it is now in receipt of ASIC and ASX approvals for the Notice of Extraordinary Meeting which will be announced and despatched to shareholders later this week.

The meeting is scheduled to be held on Tuesday, 26 February 2019.

Jarrold White
Company Secretary
Chief Financial Officer
jwhite@cardiex.com

Investor Relations
Peter Taylor
+61 412 036 231
peter@nwrcommunications.com.au

**About CardieX**

CardieX is a global health technology company that develops digital and device based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders. CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX entered into an agreement with inHealth Medical, Inc allowing CardieX to acquire up to 50.5% of inHealth by way of a convertible note.